Actively Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Led by Revolution Medicines, Inc. · Updated on 2026-04-23
534
Participants Needed
53
Research Sites
289 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
CONDITIONS
Official Title
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age
- Pathologically confirmed KRAS G12C-mutated advanced or metastatic solid tumors not amenable to curative therapy
- For Phase 1b Dose Escalation: previously treated solid tumors
- For Phase 1b Dose Expansion and Phase 2: non-small cell lung cancer previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors, or solid tumors previously treated and naïve to KRAS G12C (OFF) inhibitors
- ECOG performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Primary central nervous system tumors
- Active brain metastases
- Known gastrointestinal function impairment affecting drug absorption
- Major surgical procedures within 28 days before treatment
- Non-study related minor surgical procedures within 7 days before treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 53 locations
1
City of Hope
Duarte, California, United States, 91010
Withdrawn
2
UC IRVINE Health
Orange, California, United States, 92868
Actively Recruiting
3
UC Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Actively Recruiting
4
Stanford Cancer Institute
Stanford, California, United States, 94305
Actively Recruiting
5
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
Actively Recruiting
6
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
7
Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
Actively Recruiting
8
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
9
Henry Ford Cancer
Detroit, Michigan, United States, 48202
Withdrawn
10
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
11
Columbia University
New York, New York, United States, 10032
Actively Recruiting
12
NYU Langone Health
New York, New York, United States, 10032
Actively Recruiting
13
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
14
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
15
Sarah Cannon Research Institue
Nashville, Tennessee, United States, 37203
Actively Recruiting
16
Mary Crowley Cancer Research
Dallas, Texas, United States, 75230
Completed
17
MD Anderson
Houston, Texas, United States, 77030
Actively Recruiting
18
NEXT Dallas
Irving, Texas, United States, 75039
Actively Recruiting
19
NEXT Oncology San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
20
START Texas
San Antonio, Texas, United States, 78229
Actively Recruiting
21
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
22
West Cancer Institute
Angers, France, 49055
Actively Recruiting
23
Institut Bergonie
Bordeaux, France, 33000
Actively Recruiting
24
Hospital Louise Pradel
Bron, France, 69500
Actively Recruiting
25
Oscar Lambret Center of Lillle
Lille, France, 59000
Actively Recruiting
26
Centre Leon Berard
Lyon, France, 69373
Actively Recruiting
27
Cancer Institute of Montpellier
Montpellier, France, 34298
Actively Recruiting
28
CHU Nantes
Nantes, France, 44093
Actively Recruiting
29
Institute of Cancer of Strasbourg
Strasbourg, France, 67033
Withdrawn
30
Universitäts Klinikum Köln
Cologne, Germany, 80937
Actively Recruiting
31
Klinikum Esslingen GmbH
Esslingen am Neckar, Germany, 73730
Actively Recruiting
32
Krankenhaus Bethanien Moers
Moers, Germany, 47441
Actively Recruiting
33
Klinkum Nurnberg Paracelsus Medical Unviersity
Nuremberg, Germany, 90419
Actively Recruiting
34
Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche
Ancona, Italy, 60126
Actively Recruiting
35
Centro Di Riferimento Oncologico
Aviano, Italy, 33081
Actively Recruiting
36
Institute Romagnolo per lo Studio Tumori
Meldola, Italy, 47014
Actively Recruiting
37
Niguarda Cancer Center
Milan, Italy, 20162
Actively Recruiting
38
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
Naples, Italy, 80131
Actively Recruiting
39
San Luigi Hospital
Orbassano, Italy, 10043
Actively Recruiting
40
AUSL Romagna - S.M. delle Croci Hospital
Ravenna, Italy, 48121
Actively Recruiting
41
Netherlands Cancer Institute Antoni van Leeuwenhoek
Amsterdam, Netherlands, 1066CX
Actively Recruiting
42
Pan American Center for Oncology Trials
San Juan, Puerto Rico, 00935
Actively Recruiting
43
START Barcelona - Hospital HM Nou Delfos
Barcelona, Spain, 08023
Actively Recruiting
44
Institut Catala d'Oncologia Hospital
Barcelona, Spain, 08908
Actively Recruiting
45
University Clinic of Navarra
Madrid, Spain, 28027
Actively Recruiting
46
Fundacion MD Anderson Cancer Center
Madrid, Spain, 28033
Actively Recruiting
47
START Madrid
Madrid, Spain, 28040
Actively Recruiting
48
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
49
NEXT Oncology - Quirónsalud Madrid University Hospital
Madrid, Spain, 28223
Actively Recruiting
50
University Clinic of Navarra
Pamplona, Spain, 31008
Actively Recruiting
51
Hospital Universitario Virgen Macarena
Seville, Spain, 41009
Actively Recruiting
52
La Fe University and Polytechnic Hospital
Valencia, Spain, 46026
Actively Recruiting
53
Hospital Universitario Miguel Servet
Zaragoza, Spain, 50009
Actively Recruiting
Research Team
R
Revolution Medicines, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here